The disease burden of primary hepatocellular carcinoma (HCC): HCC ranks as the fifth most common cancer and the second leading cause of cancer-related mortality. With its high incidence and mortality rates, liver cancer has become one of the major causes of death in China. Due to its insidious onset, aggressive nature, poor sensitivity to chemotherapy, and unfavorable prognosis, liver cancer poses significant challenges in clinical treatment.
The core finding: Lactylation modification of tumor suppressor proteins leads to the loss of their antitumor functions, representing one of the key mechanisms underlying uncontrolled proliferation in HCC. Studies have demonstrated that critical tumor suppressor proteins such as p53, PTEN, PAR-4, and Rb undergo structural alterations following lactylation at specific lysine residues (e.g., p53-K120/K139, PTEN-K163), resulting in the loss of their antitumor activities. Specifically, p53 exhibits diminished DNA-binding capacity and fails to initiate cell cycle arrest or apoptosis programs; PTEN loses its phosphatase activity, leading to sustained activation of the PI3K/AKT signaling pathway and promotion of cell proliferation; while the functional inhibition of PAR-4 and Rb is also closely associated with cell cycle dysregulation. The collective loss of these tumor suppressor functions constitutes the mechanism underlying uncontrolled proliferation in HCC cells. The study was published online on August 28, 2026, in the Chinese Medical Journal .
The role mechanism: Even under aerobic conditions, HCC cells predominantly undergo glycolysis (Warburg effect) to produce substantial amounts of lactate, elevating lactate concentrations in the tumor microenvironment (TME). Lactate is recognized by AARS1 and converted into lactyl-AMP, which subsequently covalently attaches lactyl groups to lysine residues on tumor suppressor proteins (e.g., P53-K120/K139, PTEN-K163, PAR-4, Rb), forming lactylation modifications that impair these proteins' abilities to bind to DNA, exert phosphatase activity, or induce apoptosis. Following the loss of tumor suppressor protein function, tumor cells exhibit increased secretion of immunosuppressive factors such as IL-34, TGF-β, and IL-10, while TNF-α and IFN-γ levels decrease. Additionally, lactate itself inhibits CD8+ T-cell function, induces expansion of regulatory T cells (Tregs), and promotes M2 macrophage polarization, thereby creating an "immune desert" microenvironment. This immunosuppressive milieu reduces the efficacy of immune checkpoint inhibitors (e.g., anti-PD-1 agents). Animal studies demonstrate that combined use of MCT1/LDHA inhibitors or SIRT3 agonists can reverse lactylation and restore tumor suppressor protein function.
Translational strategy: HCC cells produce large amounts of lactate via the Warburg effect, activating "writing enzymes" such as AARS1/p300 to lactylate and inactivate tumor suppressor proteins like P53, PTEN, and PAR-4. Concurrently, lactate and lactylation induce Treg expansion, M2 macrophage polarization, suppression of CD8+ T-cell activity, upregulation of pro-inflammatory factors IL-10/PD-L1, and downregulation of pro-inflammatory factors TNF-α/IFN-γ, collectively fostering an immunosuppressive microenvironment. To date, no registered or ongoing HCC clinical trials have directly targeted lactylation modification as a therapeutic intervention. However, multifaceted investigations have been conducted targeting both the upstream lactate metabolism pathway and downstream effector proteins. Preclinical studies have shown that combination therapy using MCT1/LDHA inhibitors, SIRT3 agonists, and PD-1 antibodies can reduce tumor burden. In future studies, it is essential to investigate the specific mechanisms of histone acetylation in regulating tumor initiation and progression, as well as the association between non-histone acetylation and tumors and its underlying mechanisms. Additionally, the role of tumor suppressor protein acetylation in liver cancer regulation should be explored. Targeted inhibition of tumor suppressor protein lactylation combined with immune checkpoint inhibitors represents a novel strategy for liver cancer immunotherapy.